FDA Removes Black Box Warning on Estrogen: HRT Game-Changer for Women's Health
After 23 years, the FDA removed the black box warning on estrogen products—a landmark decision transforming hormone replacement therapy (HRT) for women. In this episode of the Mortar and Pestle podcast, hosts Mike De Lisio and Sebastian Dennison discuss this breakthrough with Sara Hover, Senior Director of Clinical Services at PCCA.
What You'll Learn:
Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concernsThe timing hypothesis: why age matters when starting hormone replacement therapySynthetic vs. bioidentical hormones and their clinical differencesOral estrogen delivery systems and safety implicationsShared decision-making between patients, prescribers, and pharmacistsWhy compounded HRT solutions matter for patients who don't fit commercial productsHormone testing modalities and why multiple testing methods are essentialVaginal estrogen's role in preventing UTIs and hip fracturesHow pharmacists can educate providers and patients on HRT safety
Topics Covered:
Black box warning removal, hormone replacement therapy, bioidentical hormones, menopause management, compounding pharmacy, women's health, estrogen, patient monitoring, HRT dosing strategies
Perfect for: Compounding pharmacists, healthcare providers, and anyone seeking evidence-based information on hormone replacement therapy.
Links:
The FDA Removes the Black Box Warning on Estrogen: What Pharmacists Need to Know (2025 Update)
Why VersaBase Cream Is Your Best Choice for Women's HRT
The Vaginal Microbiome, Menopause & HRT
A Personalized Approach to HRT for Perimenopausal Women
Backed by Science: Anhydrous VersaBase® HRT
Optimizing the Patient Experience with the Right HRT Base: Insights from the Webinar